Molecular Pathways: PI3-kinase pathway targets in triple negative breast cancers
Cet article passe en revue les perspectives offertes par les connaissances sur la biologie moléculaire des cancers du sein triplement négatifs pour le développement de nouveaux inhibiteurs de la voie de signalisation PI3-kinase
The triple negative breast cancer (TNBC) subtype defined clinically by the lack of estrogen, progesterone, and Her2 receptor expression, accounts for 10 to 15% of annual breast cancer diagnoses. Currently, limited therapeutic options have shown clinical benefit beyond cytotoxic chemotherapy. Defining this clinical cohort and identifying subtype specific molecular targets remains critical for new therapeutic development. The current era of high-throughput molecular analysis have revealed new insights into these targets and have confirmed the PI3-kinase as a key player in pathogenesis. The improved knowledge of the molecular basis of TNBC in parallel with efforts to develop new PI3-kinase pathway-specific inhibitors may finally produce the therapeutic breakthrough that is desperately needed.